Aptorum Group Prospectus Receives Approval for Listing on the Euronext Paris Stock Exchange
July 17 2020 - 06:20AM
Business Wire
Regulatory News:
Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a
biopharmaceutical company focusing on the development of novel
therapeutics to address global unmet medical needs, today is
pleased to announce that the French Autorité des Marchés Financiers
(“AMF”) has granted visa number 20-352 on its prospectus in
respect of its fast path cross-listing of its Class A Ordinary
Shares (the “Shares”) on the Professional Compartment of
Euronext in Paris. The Company did not issue any additional shares.
The Shares will be traded under the Euronext ticker symbol “APM”
and ISIN code: KYG6096M1069 and is expected to commence trading on
24 July 2020.
Aptorum Group’s cross-listing on Euronext Paris is believed to
help to continue to diversify Aptorum Group’s investor base and is
expected to enhance Aptorum Group’s market visibility and global
recognition, and is aligned with Aptorum Group’s strategy for the
European Union.
Mr. Ian Huen, Founder, Chief Executive Officer and Executive
Director expressed the following: “Further to our current
listing on Nasdaq, we are delighted to announce our further listing
on the Euronext Paris markets. Europe, in addition to the United
States, continues to be a key market for our company’s future
commercialization or development collaboration plans for our
portfolio of therapeutics. The European Union has in excess of 440
million1 in population and healthcare spending amounts c. 10% of
the average GDP per year2 and growing. We are confident that the
Euronext listing will continue to support the expansion of our
footprint, as well as strategically align with our key targeted
product markets in the European Union.”
Reed Smith LLP acts as Aptorum Group’s legal advisor and listing
agent. BNP Paribas Securities Services acts as Aptorum Group’s
trading agent.
About Aptorum Group
Aptorum Group Limited (Nasdaq:APM) is a pharmaceutical company
dedicated to developing and commercializing novel therapeutics to
tackle unmet medical needs. Aptorum Group’s current drug pipeline
includes indications in orphan diseases, infectious diseases and
metabolic diseases, a number of which are targeted to enter
clinical trial phases. Aptorum Group is also launching a women’s
health supplement, dioscorea opposita bioactive nutraceutical
tablets marketed under the brand name NativusWell®.
For more information about the Company, please visit our
website: www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a
solicitation of offers to buy any securities of Aptorum Group.
This announcement is an advertisement and not a prospectus
within the meaning of the Regulation (EU) n°2017/1129 of 14 June
2017 as amended by Regulations Delegated (EU) n°2019/980 of 14
March 2019 and n°2019/979 of 14 March 2019.
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as "may," "should," "expects," "plans," "anticipates,"
"could," "intends," "target," "projects," "contemplates,"
"believes," "estimates," "predicts," "potential," or "continue," or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future and the prospectus, which received the
French Autorité des Marchés Financiers visa n°20-352 on 16 July
2020. As a result, the projections included in such forward-looking
statements are subject to change and could be materially different
from those described herein. Aptorum Group assumes no obligation to
update any forward-looking statements contained in this press
release as a result of new information, future events or
otherwise.
This press release is provided ”as is” without any
representation or warranty of any kind. We assume no obligation to
update the information included in this press release, whether as a
result of new information, future events or otherwise.
________________________ 1
https://europa.eu/european-union/about-eu/figures/living_en#:~:text=The%20EU%20covers%20over%204,population%20after%20China%20and%20India.
2
https://ec.europa.eu/eurostat/web/products-eurostat-news/-/DDN-20200331-1#:~:text=On%20average%20in%20the%20EU,9.9%25%20of%20GDP%20in%202017.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200717005182/en/
Investor relations Aptorum
Group limited Investor Relations Department: +852 3953 7700
investor.relations@aptorumgroup.com
Actifin – Financial Communications Europe Investor relations
Ghislaine Gasparetto ggasparetto@actifin.fr +33 1 56 88 11 22
Redchip – Financial Communications United States Investor
relations RedChip Companies, Inc. dave@redchip.com +1 407 491
4498
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2023 to Mar 2024